ReviewCureus2025
Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Clinical and Metabolic Outcomes in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-related steatotic liver disease (MASLD) frequently coexists with inflammatory bowel disease (IBD), yet its metabolic and clinical implications remain unclear. This systematic review and meta-analysis investigated the association between MASLD and metabolic as well as IBD-related outcomes in patients with IBD. A comprehensive search of PubMed, Scopus, Google Scholar, and the Cochrane Library identified observational studies comparing IBD patients with and without MASLD. Four studies comprising 1,109 patients were included. Pooled analyses using fixed- and random-effects models showed that MASLD was significantly associated with higher odds of hypertension (odds ratio (OR) = 2.60; 95% CI: 1.76-3.85; p < 0.00001; I² = 18%) and diabetes mellitus (OR = 12.18; 95% CI: 3.37-44.10; p = 0.0001; I² = 70%), but not with IBD-related surgery (OR = 1.34; 95% CI: 0.89-2.02; p = 0.16; I² = 0%). No significant differences were found in total cholesterol (p = 0.10) or low-density lipid (LDL)-cholesterol (p = 0.07) between groups. Heterogeneity was low to moderate. In conclusion, MASLD in patients with IBD is associated with an increased risk of hypertension and diabetes but not with altered lipid profiles or need for IBD-related surgery, suggesting that MASLD is primarily associated with metabolic comorbidity rather than modification of bowel disease severity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.